Bausch Health Companies Inc.

Bausch Health Companies Inc. Earnings Recaps

BHC Health Care 2 recaps
Q3 2025 Oct 31, 2025

Bausch Health reported continued robust performance with 10 consecutive quarters of revenue and adjusted EBITDA growth, driven by strong gains in its Solta and Salix business segments.

Key takeaways
  • Q3 revenue increased 7% year-over-year to $2.681 billion, with organic growth of 5%.
  • Adjusted EBITDA reached $986 million, reflecting an 8% year-over-year rise, and 18% growth when excluding an $81 million R&D charge.
  • The Solta division saw outstanding growth of 25%, while Salix reported 12% revenue growth, fueled by strong performance in flagship products like Xifaxan.
  • The company reduced its debt by approximately $600 million, reinforcing its financial stability and allowing for raised full-year guidance across revenue, adjusted EBITDA, and cash flow.
  • Operational cash flow was steady at $508 million, demonstrating solid cash management despite working capital timing impacts.
Full recap
Q2 2025 Aug 1, 2025

Bausch Health reported robust performance in Q2 2025, achieving 5% revenue growth and a notable 10% increase in adjusted EBITDA, marking the ninth consecutive quarter of growth.

Key takeaways
  • Continued strong growth in Salix and Solta segments, contributing to double-digit revenue and EBITDA increases.
  • The completion of a $7.9 billion debt refinancing improves capital structure and extends maturities, enabling strategic flexibility.
  • Acquisition agreement for DURECT Corporation aims to leverage expertise in hepatology for alcohol hepatitis treatment development.
Full recap